Oncology biotech Exelixis is mourning the deaths of two key associates of its company immediately after getting rid of its gross sales leader and CMO in the exact same 7 days.
Gisela Schwab, M.D., the company’s president for solution enhancement and professional medical affairs and main healthcare officer, “passed absent above the weekend,” the corporation claimed. Exelixis did not notice a cause of demise.
This came just a 7 days just after Jon Berndt, its senior vice president of gross sales, handed absent last Wednesday “following a prolonged struggle with most cancers.”
Berndt, who had been at the business for six a long time, formerly led the revenue staff for Gilead’s blood most cancers drug Zydelig. Coming to Exelixis in 2015, he assisted market liver, kidney and thyroid most cancers drug Cabometyx for the corporation.
Schwab experienced been on a professional medical leave of absence due to the fact the center of June. She began out at the enterprise all the way back in 2006, getting served as CMO for an unbelievable 15 several years, aiding transform the R&D biotech into a industrial biopharma with its tyrosine kinase inhibitor Cabometyx.
“All of us at Exelixis are deeply, deeply saddened by Gisela’s passing,” explained Michael Morrissey, Ph.D., its CEO and president.
“A excellent oncologist turned medical advancement expert, Gisela was a impressive leader, mentor and mate. She was beloved by her colleagues, who ended up inspired by her strategic considering, tireless perform ethic and previously mentioned all, her unwavering commitment to increasing treatment and outcomes for individuals with cancer.
“Losing Gisela and Jon in the exact same 7 days, both of whom ended up life sciences industry veterans, is a reminder of our fragility and that most cancers is familiar with no bounds. Like Gisela, Jon was a excellent mate and colleague, and his passing is an massive loss to all who realized him and to the Exelixis loved ones.”